Fox Run Management’s BridgeBio Pharma BBIO Stock Holding History

Fox Run Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$212K	Sell	3,053 -10,670	-78%	-$773K	0.04%	749
2025 Q4	$1.05M	Buy	13,723 +776	+6%	+$50.9K	0.16%	193
2025 Q3	$672K	Sell	12,947 -50,657	-80%	-$2.47M	0.1%	375
2025 Q2	$2.75M	Buy	+63,604	New	+$2.31M	0.46%	6
2023 Q2	–	Sell	-24,551	Closed	-$407K	–	692
2023 Q1	$407K	Sell	24,551 -7,636	-24%	-$89K	0.13%	289
2022 Q4	$245K	Buy	+32,187	New	+$308K	0.1%	415

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fox Run Management's BBIO Position: Q1 2026 in Review

Fox Run Management reduced its BridgeBio Pharma (BBIO) stake by 78% in Q1 2026, selling an estimated $773K and leaving 3,053 shares worth $212K. The position accounts for 0.04% of the portfolio, ranked #749.

Fox Run Management first reported a position in BBIO in Q4 2022 and has held it in 6 quarters since. The position peaked at $2.75M in Q2 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Fox Run Management held 3,053 shares of BridgeBio Pharma worth $212K as of Q1 2026.
Fox Run Management sold 10,670 BridgeBio Pharma shares in Q1 2026, an estimated $773K.
BridgeBio Pharma made up 0.04% of Fox Run Management's portfolio in Q1 2026, its #749 holding.
Fox Run Management first reported a position in BridgeBio Pharma in Q4 2022 and has held it in 6 quarters since.
Fox Run Management's BridgeBio Pharma position peaked at $2.75M in Q2 2025.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.